Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879241 | 1.00 | ADRB2 (0.50) | ADRB2ADRB1AOC3CYP2D6NFKB1 | |
| SCHEMBL3043989 | 0.84 | TSHR (0.50) | ADRB2ADRB1HIF1ABLMTSHR | |
| SCHEMBL17755075 | 0.83 | ADRB2 (0.47) | ADRB2ADRB1AOC3CYP2D6NFKB1 | |
| SCHEMBL17790152 | 0.80 | TSHR (0.59) | ADRB2ADRB1AOC3CYP2D6NFKB1 | |
| SCHEMBL6678856 | 0.80 | ADRB2 (0.47) | ADRB2ADRB1AOC3CYP2D6NFKB1 | |
| SCHEMBL19518928 | 0.80 | TSHR (0.59) | ADRB2ADRB1AOC3CYP2D6NFKB1 | |
| SCHEMBL3789761 | 0.80 | TSHR (0.59) | ADRB2ADRB1AOC3CYP2D6NFKB1 | |
| SCHEMBL17749208 | 0.79 | ADRB2 (0.47) | ADRB2ADRB1AOC3CYP2D6NFKB1 | |
| SCHEMBL1431673 | 0.78 | NISCH (0.58) | ADRB2ADRB1AOC3CYP2D6NFKB1 | |
| SCHEMBL6683616 | 0.78 | ADRB2 (0.46) | ADRB2ADRB1AOC3CYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218356-B1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO LLC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-20210040049-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2021-02-11 | — | — | US | disclosed |
| US-20210040049-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | EVRYS BIO, LLC (US) | 2021-02-11 | — | — | US | disclosed |
| US-10723708-B2 | Anti-HCMV compositions and methods | EVRYS BIO, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723708-B2 | Anti-HCMV compositions and methods | EVRYS BIO, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC | 2018-06-21 | — | — | US | disclosed |
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC | 2018-06-21 | — | — | US | disclosed |
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC | 2018-06-21 | — | — | US | disclosed |
| EP-3218356-A2 | ANTI-HCMV COMPOSITIONS AND METHODS | Forge Life Science, LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2016077240-A2 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC (US) | 2016-05-19 | — | — | WO | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2011056652-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS (US) | 2011-05-12 | — | — | WO | disclosed |
| EP-0857171-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997015555-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723708-B2 | Anti-HCMV compositions and methods | RPL35, RPL7, RPL5 | ADRB2 4643/4885ADRB1 4602/4885AOC3 3393/4885 |
| US-20210040049-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | ADRB2 4643/4885ADRB1 4602/4885AOC3 3393/4885 |
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | ADRB2 4643/4885ADRB1 4602/4885AOC3 3393/4885 |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | IDO1, IDO2, INMT | ADRB2 2057/4885ADRB1 2207/4885AOC3 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.